Top Markets
#1 Black Phoenix Black Phoenix +822.27%
#2 MiL.k Alliance MiL.k Alliance +25.89%
#3 Beam Beam +25.14%
#4 Tutorial Tutorial +23.75%
#5 SAFEcoin SAFEcoin +19.22%
#6 Bless Bless +18.06%
#7 THORChain THORChain +16.24%
#8 EfficientFrontier EfficientFrontier +14.07%
#9 Biconomy Biconomy +13.52%
#10 Versatize Coin Versatize Coin +12.49%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Pharvaris N.V. Pharvaris N.V.

Pharvaris N.V.

PHVS
Rank in Stocks #5576
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Share Price
$36.98
Last synced: 2026-08-26
Market Cap
$2.58B
Change (1 day)
-0.67%
Change (1 year)
55.51%
Country
NL
Trade Pharvaris N.V. (PHVS)

Category

Healthcare
Revenue for Pharvaris N.V. (PHVS)
Revenue in Aug 2026 TTM: 0
According to Pharvaris N.V. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Pharvaris N.V. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH